Sarana Meditama Metropolitan (SAME) - Net Assets
Based on the latest financial reports, Sarana Meditama Metropolitan (SAME) has net assets worth Rp4.19 Trillion IDR (≈ $245.55 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rp5.77 Trillion ≈ $338.01 Million USD) and total liabilities (Rp1.58 Trillion ≈ $92.46 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check SAME tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Rp4.19 Trillion |
| % of Total Assets | 72.65% |
| Annual Growth Rate | 35.31% |
| 5-Year Change | -6.0% |
| 10-Year Change | 389.53% |
| Growth Volatility | 237.18 |
Sarana Meditama Metropolitan - Net Assets Trend (2009–2025)
This chart illustrates how Sarana Meditama Metropolitan's net assets have evolved over time, based on quarterly financial data. See Sarana Meditama Metropolitan (SAME) liquidity interval to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Sarana Meditama Metropolitan (2009–2025)
The table below shows the annual net assets of Sarana Meditama Metropolitan from 2009 to 2025. For live valuation and market cap data, see Sarana Meditama Metropolitan stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Rp4.17 Trillion ≈ $244.10 Million |
+0.66% |
| 2024-12-31 | Rp4.14 Trillion ≈ $242.49 Million |
+3.88% |
| 2023-12-31 | Rp3.98 Trillion ≈ $233.42 Million |
+0.02% |
| 2022-12-31 | Rp3.98 Trillion ≈ $233.39 Million |
-10.12% |
| 2021-12-31 | Rp4.43 Trillion ≈ $259.67 Million |
+711.91% |
| 2020-12-31 | Rp545.82 Billion ≈ $31.98 Million |
-44.16% |
| 2019-12-31 | Rp977.50 Billion ≈ $57.28 Million |
-26.29% |
| 2018-12-31 | Rp1.33 Trillion ≈ $77.70 Million |
+27.23% |
| 2017-12-31 | Rp1.04 Trillion ≈ $61.07 Million |
+22.48% |
| 2016-12-31 | Rp850.97 Billion ≈ $49.86 Million |
+14.81% |
| 2015-12-31 | Rp741.18 Billion ≈ $43.43 Million |
+287.89% |
| 2014-12-31 | Rp191.08 Billion ≈ $11.20 Million |
+43.66% |
| 2013-12-31 | Rp133.01 Billion ≈ $7.79 Million |
+591.92% |
| 2012-12-31 | Rp19.22 Billion ≈ $1.13 Million |
+575.13% |
| 2011-12-31 | Rp-4.05 Billion ≈ $-237.07K |
-149.69% |
| 2010-12-31 | Rp8.14 Billion ≈ $477.11K |
-75.33% |
| 2009-12-31 | Rp33.00 Billion ≈ $1.93 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Sarana Meditama Metropolitan's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 8454620900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Rp343.12 Billion | 9.03% |
| Other Comprehensive Income | Rp431.00 Billion | 11.34% |
| Other Components | Rp3.11 Trillion | 81.86% |
| Total Equity | Rp3.80 Trillion | 100.00% |
Sarana Meditama Metropolitan Competitors by Market Cap
The table below lists competitors of Sarana Meditama Metropolitan ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hubtown Limited
NSE:HUBTOWN
|
$299.73 Million |
|
Bintang Oto Global Tbk PT
JK:BOGA
|
$299.76 Million |
|
Vodafone Group PLC
LSE:VOD
|
$299.78 Million |
|
Colonial Coal International Corp
V:CAD
|
$299.82 Million |
|
UNID Company Ltd
KO:014830
|
$299.64 Million |
|
EuroHold Bulgaria AD
WAR:EHG
|
$299.59 Million |
|
AVCON Information Tech
SHE:300074
|
$299.56 Million |
|
Eledon Pharmaceuticals Inc
NASDAQ:ELDN
|
$299.49 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Sarana Meditama Metropolitan's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 3,780,421,309,000 to 3,801,240,824,000, a change of 20,819,515,000 (0.6%).
- Net income of 30,075,777,000 contributed positively to equity growth.
- Other comprehensive income decreased equity by 11,519,385,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Rp30.08 Billion | +0.79% |
| Other Comprehensive Income | Rp-11.52 Billion | -0.3% |
| Other Changes | Rp2.26 Billion | +0.06% |
| Total Change | Rp- | 0.55% |
Book Value vs Market Value Analysis
This analysis compares Sarana Meditama Metropolitan's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.35x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 84.48x to 1.35x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | Rp3.53 | Rp298.00 | x |
| 2013-12-31 | Rp14.73 | Rp298.00 | x |
| 2014-12-31 | Rp21.08 | Rp298.00 | x |
| 2015-12-31 | Rp81.76 | Rp298.00 | x |
| 2016-12-31 | Rp93.87 | Rp298.00 | x |
| 2017-12-31 | Rp114.97 | Rp298.00 | x |
| 2018-12-31 | Rp146.28 | Rp298.00 | x |
| 2019-12-31 | Rp107.82 | Rp298.00 | x |
| 2020-12-31 | Rp53.25 | Rp298.00 | x |
| 2021-12-31 | Rp283.29 | Rp298.00 | x |
| 2022-12-31 | Rp211.50 | Rp298.00 | x |
| 2023-12-31 | Rp212.17 | Rp298.00 | x |
| 2024-12-31 | Rp220.47 | Rp298.00 | x |
| 2025-12-31 | Rp221.55 | Rp298.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Sarana Meditama Metropolitan utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.79%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 1.62%
- • Asset Turnover: 0.32x
- • Equity Multiplier: 1.53x
- Recent ROE (0.79%) is below the historical average (8.47%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 121.04% | 8.60% | 0.93x | 15.13x | Rp21.35 Billion |
| 2013 | 35.07% | 13.86% | 0.89x | 2.84x | Rp33.35 Billion |
| 2014 | 30.39% | 14.01% | 0.89x | 2.44x | Rp38.96 Billion |
| 2015 | 7.64% | 10.99% | 0.43x | 1.62x | Rp-17.51 Billion |
| 2016 | 1.74% | 2.33% | 0.44x | 1.71x | Rp-70.30 Billion |
| 2017 | 6.91% | 9.29% | 0.45x | 1.65x | Rp-32.21 Billion |
| 2018 | 4.44% | 6.18% | 0.38x | 1.91x | Rp-73.72 Billion |
| 2019 | -11.70% | -21.61% | 0.24x | 2.28x | Rp-212.13 Billion |
| 2020 | -82.35% | -88.54% | 0.27x | 3.46x | Rp-504.05 Billion |
| 2021 | 3.76% | 11.34% | 0.26x | 1.29x | Rp-239.52 Billion |
| 2022 | 0.26% | 0.69% | 0.27x | 1.42x | Rp-352.70 Billion |
| 2023 | 0.34% | 0.80% | 0.29x | 1.48x | Rp-351.35 Billion |
| 2024 | 0.31% | 0.69% | 0.31x | 1.47x | Rp-366.19 Billion |
| 2025 | 0.79% | 1.62% | 0.32x | 1.53x | Rp-350.05 Billion |
Industry Comparison
This section compares Sarana Meditama Metropolitan's net assets metrics with peer companies in the Medical Care Facilities industry.
Industry Context
- Industry: Medical Care Facilities
- Average net assets among peers: $4,866,919,291,058
- Average return on equity (ROE) among peers: 15.25%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Sarana Meditama Metropolitan (SAME) | Rp4.19 Trillion | 121.04% | 0.38x | $299.72 Million |
| Bundamedik Tbk PT (BMHS) | $1.81 Trillion | 7.13% | 0.63x | $92.26 Million |
| Metro Healthcare Indonesia (CARE) | $2.27 Trillion | -1.06% | 0.08x | $806.60 Million |
| Medikaloka Hermina PT (HEAL) | $5.87 Trillion | 9.14% | 0.80x | $796.84 Million |
| Lippo Karawaci Tbk (LPKR) | $22.08 Trillion | 4.00% | 1.07x | $257.49 Million |
| Mitra Keluarga Karyasehat Tbk PT (MIKA) | $7.33 Trillion | 15.64% | 0.13x | $1.30 Billion |
| Royal Prima PT (PRIM) | $12.13 Billion | 95.19% | 2.15x | $17.22 Million |
| Kedoya Adyaraya Tbk PT (RSGK) | $751.16 Billion | 3.35% | 0.10x | $47.12 Million |
| Siloam International Hospitals (SILO) | $3.13 Trillion | 2.75% | 0.35x | $1.65 Billion |
| Sejahteraraya Anugrahjaya Tbk (SRAJ) | $556.74 Billion | 1.08% | 0.31x | $7.89 Billion |
About Sarana Meditama Metropolitan
PT Sarana Meditama Metropolitan Tbk engages in the hospital management of EMC Hospital Pulomas in Pulomas, East Jakarta. The company operates specialty centers. It also is involved in trading of medical equipment; healthcare pharmacy; real estate; and agriculture. The company was founded in 1984 and is based in Jakarta, Indonesia. PT Sarana Meditama Metropolitan Tbk is a subsidiary of PT Elang Ma… Read more